By Editorial TeamThe AI health sector is experiencing unprecedented velocity, driven by a confluence of technological advancement, growing market demand, and a maturing regulatory landscape. For investors and health plan executives, discerning true growth and sustainable innovation amidst the noise requires a sophisticated framework that moves beyond simple funding rounds. This is precisely the impetus behind the AI Health Momentum Index.
The AI Health Momentum Index: Tracking Expansion Velocity
The AI Health Momentum Index offers a critical lens through which to evaluate the trajectory of AI health companies. It synthesizes three core dimensions: revenue growth, deployment expansion, and evidence accumulation. This integrated approach acknowledges that in a highly regulated and evidence-driven sector like healthcare, financial performance alone is insufficient. Instead, the index prioritizes companies demonstrating robust commercial traction through extensive health-plan relationships and Fortune 500 deployments, alongside a deep commitment to clinical validation and regulatory de-risking. The argument is clear: validated AI health companies, those with a strong evidentiary foundation, are not just surviving but thriving and growing faster as regulatory scrutiny intensifies.
Index Methodology: Categories, Weighting, and Inclusion
Our index methodology is designed to provide a comprehensive, data-driven assessment.
Revenue Growth: This component tracks year-over-year revenue increases, focusing on recurring revenue streams indicative of long-term contracts and sustained adoption. For publicly traded entities, this is derived from financial disclosures. For private companies, we analyze reported growth validated through investor briefings and market intelligence, often framed through the lens of enterprise contract depth. High revenue growth signals market acceptance and effective commercialization strategies.
Deployment Expansion: This dimension evaluates the breadth and depth of a company’s market penetration. Key metrics include the number of health plan relationships, the volume of covered lives, and the scale of Fortune 500 enterprise deployments. A strong showing here indicates successful integration into established healthcare ecosystems and a capacity for scalable rollout. This includes monitoring the expansion of employer-sponsored programs and direct health plan partnerships. Analysis of health plan adoption rates for digital health solutions
Evidence Accumulation: This crucial component assesses the quality and quantity of clinical evidence supporting an AI solution’s efficacy and safety. This includes peer-reviewed publications, randomized controlled trials (RCTs), real-world evidence (RWE) generation, and regulatory clearances (e.g., 510(k), De Novo, Breakthrough Device Designation). Companies that invest heavily in robust clinical validation not only build trust but also de-risk future regulatory hurdles and strengthen their position for reimbursement. Eric Topol has consistently emphasized the imperative of rigorous evidence in digital health, a sentiment echoed by Vinod Khosla regarding the necessity of demonstrable outcomes for AI’s impact in healthcare. Eric Topol’s perspectives on digital health evidence
Each dimension is weighted to reflect its impact on long-term sustainable growth and market dominance. Revenue growth and deployment expansion carry significant weight, reflecting commercial success, while evidence accumulation is a critical foundational factor that mitigates risk and unlocks broader adoption, especially as regulatory bodies like the FDA mature their approach to AI/ML medical devices, emphasizing GMLP (Good Machine Learning Practice) and the need for QMS / ISO 13485 certification.
Current Leaders in the AI Health Momentum Index
Analyzing a selection of prominent AI health companies against these dimensions reveals distinct patterns of growth and strategic focus.
- Hinge Health: A leader in digital musculoskeletal care, Hinge Health demonstrates significant deployment expansion, boasting extensive health plan relationships and a strong presence within Fortune 500 companies, with clients representing 53% of the Fortune 100 and 45% of the Fortune 500 as of early 2026. Their growth is underpinned by substantial employer and health-plan expansion signals, indicating deep enterprise contract depth, with contracted lives expanding to 25 million by the end of 2025. Their focus on RWE further solidifies their position, and they have expanded their offerings to include a migraine program with an FDA-cleared wearable and orthopedic surgery.
- iRhythm Technologies: As a publicly traded entity, iRhythm’s revenue growth is transparently reported, driven by its Zio XT patch. Their success highlights the power of a data moat, built on over 10 million patient reports and more than 2 billion hours of curated heartbeat data since inception, making it difficult for competitors to match their diagnostic accuracy. This strong evidence base and clear regulatory pathway, including multiple 510(k) clearances for design modifications and labeling updates for its Zio AT device in late 2024, have fueled their deployment expansion.
- Omada Health: Omada Health, a Nasdaq-listed company, excels in deployment expansion through partnerships with health plans and employers for chronic disease management. Their growth strategy emphasizes covered-lives volume, indicating broad market penetration and strong health-plan integration, with total members crossing 1 million for the first time in Q1 2026. The company reported full-year 2025 revenue of $260 million and projects 2026 revenue between $322 million and $330 million.
- HeartFlow: This company has built a patent thicket around CT-FFR, demonstrating a strategic approach to market protection. HeartFlow’s technology has been adopted by more than 1,400 institutions globally and has redefined care for over 500,000 patients worldwide, supported by more than 600 peer-reviewed publications. Their proprietary data pipeline is built from more than 160 million annotated CTA images. Their revenue expansion is driven by increasing adoption in cardiology practices, supported by clinical evidence demonstrating improved diagnostic pathways, with Q1 2026 revenue reaching $52.6 million, a 41% increase year-over-year.
- Spring Health: Focusing on mental health, Spring Health has achieved remarkable deployment expansion, securing numerous Fortune 500 contracts and health plan partnerships. Their growth signals strong demand for scalable, AI-driven mental healthcare solutions and a robust employer expansion strategy. In early 2026, Spring Health acquired Alma, creating a combined platform that supports over 170 million lives. They also launched “Guide,” an AI-led experience clinically proven to improve mental health outcomes.
- Tempus AI: Tempus AI, a Nasdaq-listed company, exhibits strong revenue growth driven by its AI-powered precision medicine platform, which integrates clinical and molecular data. Their deployment expansion is evident in their partnerships with healthcare systems and pharmaceutical companies, leveraging their vast proprietary datasets to provide diagnostic and therapeutic insights. The company reported Q4 2025 revenue of $367.2 million and projects full-year 2026 revenue between $1.59 billion and $1.60 billion. Tempus has also launched an Open-Source Digital Pathology Consortium and validated an AI-enabled ECG model for predicting Atrial Fibrillation Risk.
- Viz.ai: Viz.ai stands out for its rapid deployment expansion within hospital systems, particularly for stroke care. Their AI-driven solutions, often operating as SaMD, demonstrate clear enterprise contract depth, improving clinical workflows and patient outcomes. Their regulatory clearances, including multiple 510(k) clearances for tools like Viz Subdural Plus for subdural measurements, Viz ICH Plus for intracerebral hemorrhage quantification, and Viz ANEURYSM for cerebral aneurysm detection, and growing body of RWE underpin their momentum. By 2024, the company generated $48.8 million in revenue.
These companies exemplify how a combination of aggressive market penetration (deployment expansion), robust financial performance (revenue growth), and a commitment to clinical rigor (evidence accumulation) drives momentum in the AI health sector.
Governance Context and Market Dynamics
The evolving governance landscape plays a pivotal role in shaping the growth trajectories of AI health companies. Organizations like Rock Health and CB Insights consistently track funding trends and market shifts, highlighting the increasing investor preference for companies with clear regulatory pathways and strong clinical validation. Goldman Sachs Healthcare analysts frequently emphasize the importance of evidence-based solutions for long-term payer adoption and reimbursement. For publicly traded companies like iRhythm, Nasdaq listings provide a transparent view of market confidence, where sustained growth often correlates with consistent clinical outcomes and expanding market share. The increasing regulatory scrutiny, far from being a deterrent, acts as an accelerant for validated AI health companies. Those that proactively engage with GMLP principles and secure necessary clearances are better positioned to scale, attract investment, and secure crucial health plan contracts. The ability to navigate the complexities of 510(k) clearance, or even De Novo classification for truly novel AI functions, is a significant de-risking factor for investors.
Utilizing and Updating the AI Health Momentum Index
The AI Health Momentum Index serves as a dynamic tool for both investors and health plan executives. For investors, it offers a framework for identifying companies with sustainable growth potential, factoring in not just immediate financial returns but also the long-term viability derived from clinical evidence and market penetration. It helps pinpoint companies that are building a data moat and strategically navigating the patent thicket. For health plan executives, the index provides a benchmark for evaluating potential partners, ensuring that adopted solutions are not only innovative but also clinically validated and capable of broad, effective deployment across covered lives. The index will be regularly updated to reflect new data on revenue, deployment milestones (employer and health-plan expansion signals, covered-lives volume), and the ongoing accumulation of clinical evidence. This iterative approach ensures that the AI Health Momentum Index remains a timely and authoritative guide in the rapidly evolving AI health landscape. Latest digital health investment trends from Rock Health
Frequently Asked Questions
A1: How does the AI Health Momentum Index identify companies with ‘true growth’ beyond just funding rounds?
The Index evaluates companies based on three core dimensions: revenue growth, deployment expansion, and evidence accumulation. This integrated approach acknowledges that financial performance alone is insufficient in a highly regulated and evidence-driven sector like healthcare. It prioritizes companies demonstrating robust commercial traction and a deep commitment to clinical validation and regulatory de-risking.
A1: What specific metrics does the Index use to assess a company’s potential for long-term sustainable growth and market dominance?
The Index uses year-over-year recurring revenue increases for revenue growth, and for deployment expansion, it tracks the number of health plan relationships, covered lives, and Fortune 500 enterprise deployments. Evidence accumulation is assessed through peer-reviewed publications, randomized controlled trials, real-world evidence generation, and regulatory clearances. These dimensions are weighted to reflect their impact on long-term sustainable growth and market dominance.
A2: How does the AI Health Momentum Index help health plan executives identify reliable AI solutions for their members?
The Index prioritizes companies demonstrating robust commercial traction through extensive health-plan relationships and Fortune 500 deployments. It also assesses the quality and quantity of clinical evidence supporting an AI solution’s efficacy and safety, including peer-reviewed publications and regulatory clearances. This focus helps identify validated AI health companies that have built trust and de-risked future regulatory hurdles.
A2: What emphasis does the Index place on clinical validation and regulatory compliance for AI health companies?
Evidence accumulation is a crucial component of the Index, assessing clinical evidence like peer-reviewed publications, RCTs, and regulatory clearances (e.g., 510(k), De Novo). Companies that invest heavily in robust clinical validation not only build trust but also de-risk future regulatory hurdles and strengthen their position for reimbursement. This is critical as regulatory bodies mature their approach to AI/ML medical devices, emphasizing GMLP and QMS/ISO 13485 certification.
